Skip to content

Evaluation of the efficacy of Zinc sulfate and fluoxetine in obsessive_compulsive

Evaluation of the efficacy of zinc sulfate and fluoxetine in comparison with fluoxetine with placebo in children and adolescents with obsessive-compulsive disorder

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160530028182N11
Enrollment
42
Registered
2023-10-10
Start date
2022-08-16
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obssesive_compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: "Intervention group:" for this group, patients fluoxetine capsules manufactured by Obeid company for the first week (daily, 5 mg in the morning), the second week (daily, 10 mg in the m

Sponsors

Kurdistan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 17 Years

Inclusion criteria

Inclusion criteria: Age 10-17 years Based on the diagnostic criteria of DSM-5, obsessive-compulsive disorder should be diagnosed in children by a specialist in child and adolescent psychiatry.

Exclusion criteria

Exclusion criteria: Existence of accompanying psychiatric disorder except for anxiety disorders and oppositional defiant disorder- Mental retardation based on clinical suspicion History of allergy to zinc sulfate Wilson's disease according to medical statements and documents Liver disease based on medical statements and documents Spending drug treatments in the previous 2 months Suicidal thoughts

Design outcomes

Primary

MeasureTime frame
Obsessive compulsive scor in Fua et al.'s 2010 Obsessive Compulsive Questionnaire, Children's Version, 21 items (OCI-CV). Timepoint: At the beginning of the study, 4 weeks later, at the end of 8 weeks. Method of measurement: Fowa et al.'s 2010 Children's Version 21-item Obsession Questionnaire (OCI-CV).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoleiman Mohammadzadeh

Kurdistan University of Medical Sciences

dr.mohammadzadeh86@muk.ac.ir+98 87 3323 2168

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026